4 Undervalued Pharmaceuticals Stocks for Friday, August 14
Discover the top 4 undervalued Pharmaceuticals stocks for Friday, August 14 based on AAII’s Stock Grades.Michael Rose
Stock Evaluator: Indivior Pharmaceuticals, Inc. (INDV)
Indivior Pharmaceuticals, Inc. INDV
$35.00
-0.05
-0.14%
September 3, 2026 9:31:08 AM
EST
Volume: 90,189
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Commentary & Analysis
Why Indivior Pharmaceuticals, Inc.’s (INDV) Stock Is Up 5.22%
As of Wednesday, August 05, Indivior Pharmaceuticals, Inc.’s INDV share price has surged by 5.22%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Which Is a Better Investment, Indivior Pharmaceuticals, Inc. or Trulieve Cannabis Corp. Stock?
Learn more about whether Indivior Pharmaceuticals, Inc. or Trulieve Cannabis Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Why Indivior Pharmaceuticals, Inc.’s (INDV) Stock Is Up 6.48%
As of Thursday, June 04, Indivior Pharmaceuticals, Inc.’s INDV share price has surged by 6.48%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Indivior Pharmaceuticals, Inc.’s (INDV) Stock Is Down 5.91%
As of Tuesday, June 02, Indivior Pharmaceuticals, Inc.’s INDV share price has dipped by 5.91%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | INDV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,136.4 | $674.0 | 64% |
|
| Shares Out (Mil) | 124.0 | 43.9 | 67% |
|
| Institutional Ownership | 98.2% | 84.7% | 78% |
|
| Float (Mil) | 115.8 | 47.3 | 64% |
|
| Beta | 1.14 | 0.71 | 68% |
|
| Avg Daily Volume (000s) | 1,947 | 293 | 83% |
|
| Price Change (52-week) |
42.5% | 68.8% | 78% |
|
| Growth | INDV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 13.9% | 6.8% | 70% |
|
| Net Income (5yr) | 27.9% | (1.5%) | 83% |
|
| EPS (5yr) | 29.4% | 14.9% | 80 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 6.4% | (15.1%) | 68% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 3 | 3 | |
| Current EPS | $1.119 | $4.409 | $4.883 | |
| Month Ago EPS | $0.981 | $3.855 | $4.168 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.990 | $3.853 | $3.920 | |
| Year/Year Chg | 14.2% | 168.8% | 221.0% | |
| Financials | INDV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,331 | $317 | 54% |
|
| Net Income (TTM) (Mil) | $356 | ($11) | 74% |
|
| EPS (TTM) | $2.883 | ($0.700) | 77% |
|
| Operating Cash Flow (TTM) (Mil) | ($40) | ($7) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($287) | $4 | 8% |
|
| Long-Term Debt (Q1) (Mil) | $500 | $6 | 59% |
|
| Enterprise Value (Q1) (Mil) | $4,366 | $575 | 60% |
|
| Valuation | INDV | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.80 | na |
|
| P/E | 12.7 | 17.4 | 29% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.4 | 1.1 | 20% |
|
| Ratios | INDV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 85.7% | 67.5% | 91% |
|
| Net Margin | 26.7% | (1.4%) | 85% |
|
| ROA | 26.5% | (24.6%) | 98% |
|
| ROE | (153.1%) | (21.4%) | 6% |
|
| Liabilities to Assets | 116.9% | 32.2% | 96% |
|
| F-Score | 5 | 3 | 50% |
|
Indivior Pharmaceuticals, Inc. did not pass any screens on 9/2/2026.
